Clinical trials: Cardiovascular (CV) Risk
Weight Management, Cardiovascular (CV) Risk
Feasibility, Acceptability, and Validation of a User-friendly Diet Quality Tool in Adults From Ambulatory Nutrition Clinics
The study design for Perceptions and Learning About a Diet Tool (PLATE) was a prospective online dietary intake survey in adults engaged in ambulatory nutrition counseling.
- Conditions
- Weight Management, Cardiovascular (CV) Risk, Metabolic and Nutritional Disorders
- Trial name
- PLATE (NCT07109011)
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- University of Pennsylvania
Glycemia, Hypertension
Effect of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).
This study will address the proportion of achievement patients in treatment target goal on glycemic control, hypertension and hyperlipidemia according to ADA 2008 guideline, among outpatients coming to the Korean primary care…
- Conditions
- Glycemia, Hypertension, Hyperlipidemia
- Trial name
- PATROL (NCT00891124)
- Where
- 7 sites in South Korea
- Volunteers
- 4,045 people
- Sponsor
- AstraZeneca
Cardiovascular Diseases, Heart Diseases
Risk Factors for CV Disease in a Dialysis Cohort
To investigate whether traditional risk factors and novel risk factors predict higher risk of atherosclerotic cardiovascular disease (ASCVD) in a prospective study of incident dialysis patients.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Atherosclerosis, Kidney Failure, Chronic
- Trial name
- NCT00006297
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Coronary Disease, Cardiovascular Diseases
Examining How Heart Disease Risk Factors Affect Healthy Aging (The Chicago Healthy Aging Study [CHAS])
Heart disease is the leading cause of death in the United States and is responsible for 30% of all deaths in the United States. This study will examine how risk factors for heart disease in young and middle aged people affect…
- Trial name
- CHAS (NCT00626379)
- Where
- United States
- Volunteers
- 1,395 people
- Sponsor
- Northwestern University
Coronary Disease, Diabetes Mellitus
A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To demonstrate if torcetrapib/atorvastatin can reduce the risk for major cardiovascular disease events, when compared to atorvastatin alone, in…
- Trial name
- ILLUMINATE (NCT00134264)
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 221 sites in United States, Australia and 5 more
- Volunteers
- 15,067 people
- Sponsor
- Pfizer
Breast Cancer, Cardiovascular (CV) Risk
Multicenter Cardiac Decision Impact Study in People With Breast Cancer
Background: Breast cancer is the most common cancer in women, and advances in early detection and treatment have led to steadily improved survival rates. Today, nearly 80% of breast cancer survivors are over 50 years of age.
- Conditions
- Breast Cancer, Cardiovascular (CV) Risk, Coronary Artery Calcifications
- Trial name
- CarDI (NCT07703033)
- Testing
- Measuring coronary artery calcifications (Agatston score) using routine radiotherapy planning CT scans and communicating the associated risk of cardiovascular disease to the patient.
- Where
- 5 sites in Denmark, Germany and 2 more
- Volunteers
- 1,000 people
- Sponsor
- UMC Utrecht
Rheumatoid Arthritis, Atherosclerotic Ischemic Disease
Coronary Computed Tomography Angiography In Rheumatoid Arthritis Study
The Coronary Computed Tomography Angiography in Rheumatoid Arthritis study is part of the multinational, prospective, observational Autoimmunity and Atherosclerosis in Rheumatic Diseases cohort (https://atacc-rd.com) that…
- Conditions
- Rheumatoid Arthritis, Atherosclerotic Ischemic Disease, Pulmonary Disease, Depressive Disorder
- Trial name
- COTIRA (NCT07363980)
- Where
- 4 sites in Denmark
- Volunteers
- 4,000 people
- Sponsor
- Ellen Margrethe Hauge
Hypercholesterolemia
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
This is a randomized, double-blind, double-dummy, active-controlled, parallel-group, multi-national, multi-center study to compare alirocumab (REGN727/SAR236553) versus ezetimibe in participants with primary hypercholesterolemia…
- Trial name
- NCT01709513
- Testing
- Atorvastatin, Ezetimibe, Alirocumab
- Where
- 70 sites in United States, Austria and 6 more
- Volunteers
- 314 people
- Sponsor
- Regeneron Pharmaceuticals
Cardiovascular Risk Factor, Hypertension
A Web-based Platform to Conduct Trials of mHealth Apps for Hypertension
Self-management of cardiovascular (CV) risk factors is a recommended form of secondary disease prevention. There are thousands of consumer-facing mobile health (mHealth) applications (apps) intended for tracking, monitoring, and…
- Trial name
- NCT04528654
- Testing
- Mobile Health Application
- Where
- 2 sites in Canada
- Volunteers
- 5 people
- Sponsor
- McMaster University
Atherosclerosis, Cardiovascular Disease
Homocysteine Lowering and Atherosclerosis Reduction Trial (HART)
Study Objective: 1. To evaluate whether combined therapy with folic acid 2.5 mg/day, vitamin B6 50 mg/day and vitamin B12 1000 micrograms/day vs placebo reduces the rate of atherosclerosis progression, as evaluated by…
- Trial name
- NCT00217178
- Testing
- Vitamins: Folic acid, B6, B12
- Where
- Canada
- Volunteers
- 900 people
- Sponsor
- Hamilton Health Sciences Corporation
Hypercholesterolaemia
Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Primary Objective: To collect real-use (usability) data assessing the robustness and user interaction of the new alirocumab auto-injector device (which is referred to as SYDNEY), in unsupervised settings.
- Trial name
- NCT03415178
- Testing
- Alirocumab SAR236553, Current auto-injector device (AI), New auto-injector device (SYDNEY)
- Where
- 13 sites in United States
- Volunteers
- 69 people
- Sponsor
- Sanofi
Cardiovascular (CV) Risk
Cardiovascular Prevention Supported by Digital Technology: Comparison With the Traditional Model
Cardiovascular diseases represent one of the leading causes of morbidity and mortality worldwide. Prevention in patients at cardiovascular risk is essential to reduce the incidence of cardiovascular events and slow the…
- Trial name
- DIGITAL PREV (NCT07608926)
- Testing
- Recommendations to the patient.
- Where
- Italy
- Volunteers
- 144 people
- Sponsor
- Maria Cecilia Hospital
Hypertension, OSA - Obstructive Sleep Apnea
Primary Prevention Long-term Registry Study in OSA and Hypertension. Survival Analysis 2010-2022
Hypertension and obstructive sleep apnea (OSA) are both common conditions that independently increase the risk cardiovascular disease including atrial fibrillation, ischemic heart disease, heart failure and stroke.
- Conditions
- Hypertension, OSA - Obstructive Sleep Apnea, MACE, Survival Analysis
- Trial name
- DISCOVERY-HT (NCT06930989)
- Testing
- Positive airway pressure (PAP)
- Where
- Sweden
- Volunteers
- 148,467 people
- Sponsor
- Vastra Gotaland Region
Cardiovascular (CV) Risk, Healthy Eating Index
Pulses: Optimizing Pulse Consumption for Cardiometabolic Health
This randomized clinical trial aims to evaluate the effects of consuming two different doses of pulses (1.5 cups/week or 3 cups/week) in individuals with baseline intake below 1.5 cups/week, compared to a control group receiving…
- Conditions
- Cardiovascular (CV) Risk, Healthy Eating Index, HbA1c, Lipid Profile
- Trial name
- NCT06861153
- Testing
- Pulses 1.5 cups Group, Pulses 3 cups Group, My Plate Group (Control)
- Where
- 2 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Endothelial Function, Aerobic Exercise
VascuFit: Exercise and Vascular Aging
Exercise is a cornerstone of health care helping to improve and maintain a good organ functionality, including vascular function, in health and disease.
- Conditions
- Endothelial Function, Aerobic Exercise, Middle-aged Adults Sedentary, Elevated CV-risk)
- Trial name
- VascuFit (NCT05235958)
- Testing
- non-linear periodized exercise (NLPE), Exercise counselling
- Where
- Switzerland
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Karsten Königstein
Heart Attack, Stroke
CV Wizard: Does a Clinical Decision Support Tool Improve CVD Risk Factor Control in Safety Net Clinics?
This project aims to reduce disparities in cardiovascular disease (CVD) risk factor control and in rates of heart attacks and strokes among the low-income, racially / ethnically diverse Americans who receive primary care at…
- Conditions
- Heart Attack, Stroke, Cardiovascular Diseases
- Trial name
- CV_WIZARD (NCT03001713)
- Testing
- CV WIZARD
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Acute Coronary Syndrome
Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
A placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile.
- Trial name
- dal-GenE (NCT02525939)
- Testing
- dalcetrapib
- Where
- 557 sites in United States, Argentina and 30 more
- Volunteers
- 6,147 people
- Sponsor
- DalCor Pharmaceuticals
Hypertension
Impact of Ramadan on Achieving Joint National Committee (JNC) 7 Treatment Goals in CV Risk Patients
This is an out-patient based prospective, multi-centre, observational post-marketing surveillance study amongst internists and cardiologists.
- Trial name
- NCT01853839
- Where
- 132 sites in Algeria, Egypt and 3 more
- Volunteers
- 1,674 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus, CV Risk
Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects
The primary objective of this study is to assess the total CV risk in patients with type 2 diabetes and also to assess the impact of rosiglitazone in the total CV risk and the parameters of metabolic syndrome.
- Trial name
- NCT00648284
- Volunteers
- 1,100 people
- Sponsor
- GlaxoSmithKline
Cardiovascular (CV) Risk
Democratizing Access to Cleaner Residential Air
The purpose of this research study is to determine whether the use of in-home air filtration to reduce exposure to air pollution benefits health.
- Trial name
- DACRA (NCT07629518)
- Testing
- Portable air purifiers with HEPA filtration
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Douglas Brugge